Edition:
India

Inovio Pharmaceuticals Inc (INO.OQ)

INO.OQ on NASDAQ Stock Exchange Global Select Market

4.40USD
17 Jan 2018
Change (% chg)

$0.02 (+0.46%)
Prev Close
$4.38
Open
$4.38
Day's High
$4.43
Day's Low
$4.28
Volume
217,046
Avg. Vol
299,288
52-wk High
$9.85
52-wk Low
$4.09

Select another date:

Tue, Jan 9 2018

BRIEF-Inovio Pharmaceuticals, Parker Institute For Cancer Immunotherapy Establish Clinical Development Collaboration To Evaluate Novel Cancer Immunotherapy Combinations

* INOVIO PHARMACEUTICALS AND THE PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY ESTABLISH CLINICAL DEVELOPMENT COLLABORATION TO EVALUATE NOVEL CANCER IMMUNOTHERAPY COMBINATIONS

BRIEF-Inovio Receives Milestone Payment From Medimmune

* INOVIO RECEIVES MILESTONE PAYMENT FROM MEDIMMUNE AS MEDI0457 AND CHECKPOINT INHIBITOR COMBINATION TRIAL IN HEAD AND NECK SQUAMOUS CELL CANCER ADVANCES TO PHASE 2 Source text for Eikon: Further company coverage:

BRIEF-Inovio Enters License, Collaboration Agreement With Apollobio To Develop, Commercialize VGX-3100 In Greater China

* INOVIO ENTERS LICENSE AND COLLABORATION AGREEMENT WITH APOLLOBIO TO DEVELOP AND COMMERCIALIZE VGX-3100 IN GREATER CHINA

BRIEF-‍Inovio Pharma Cancer Vaccine Shows Promise In Preclinical Trial

* ‍INOVIO PHARMACEUTICALS SYNCON TERT CANCER IMMUNOTHERAPY COMBINED WITH CHECKPOINT INHIBITOR SYNERGISTICALLY SHRINKS TUMOR,IMPROVES SURVIVAL IN PRECLINICAL TUMOR MODEL​ Source text for Eikon: Further company coverage:

BRIEF-Inovio pharmaceuticals reports 2017 third quarter financial results

* Inovio Pharmaceuticals reports 2017 third quarter financial results

BRIEF-Inovio Pharma says ‍on Oct 30, Apollobio board approved agreements of license & collaboration agreement with co which was announced on July 14

* Inovio Pharmaceuticals says ‍on Oct 30, Apollobio board approved agreements of license & collaboration agreement with co which was announced on July 14

BRIEF-Inovio Pharma initiates immuno-oncology clinical study for glioblastoma

* Inovio Pharmaceuticals initiates immuno-oncology clinical study for glioblastoma in combination with Regeneron’S PD-1 inhibitor Source text for Eikon: Further company coverage:

BRIEF-Inovio Pharmaceuticals reports positive results from phase 1 trial of zika virus vaccine

* Inovio Pharmaceuticals Inc ‍reported on positive safety and immune response results from phase 1 trial of a vaccine against zika virus​

Zika vaccine shows promise in early human trial

CHICAGO A DNA-based Zika vaccine from Inovio Pharmaceuticals Inc and South Korea's GeneOne Life Science Inc induced anti-Zika immune responses in an early stage human trial, U.S. researchers reported on Wednesday.

BRIEF-Inovio and partners initiate Phase 1/2A clinical trial to further advance its vaccine against deadly MERS infection

* Inovio and partners initiate Phase 1/2A clinical trial to further advance its vaccine against deadly MERS infection

Select another date: